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Abstract: Aberrantly activated Wnt signaling causes cellular transformation that can lead to human 
colorectal cancer. Wnt signaling is mediated by Lymphoid Enhancer Factor/T-Cell Factor 
(LEF/TCF) DNA-binding factors. Here we investigate whether altered LEF/TCF expression is 
conserved in human colorectal tumor sample and may potentially be correlated with indicators of 
cancer progression. We carried out a meta-analysis of carefully selected publicly available gene 
expression data sets with paired tumor biopsy and adjacent matched normal tissues from colorectal 
cancer patients. Our meta-analysis confirms that among the four human LEF/TCF genes, LEF1 and 
TCF7 are preferentially expressed in tumor biopsies, while TCF7L2 and TCF7L1 in normal control 
tissue. We also confirm positive correlation of LEF1 and TCF7 expression with hallmarks of active 
Wnt signaling (i.e., AXIN2 and LGR5). We are able to correlate differential LEF/TCF gene 
expression with distinct transcriptomes associated with cell adhesion, extracellular matrix 
organization, and Wnt receptor feedback regulation. We demonstrate here in human colorectal 
tumor sample correlation of altered LEF/TCF gene expression with quantitatively and qualitatively 
different transcriptomes, suggesting LEF/TCF-specific transcriptional regulation of Wnt target 
genes relevant for cancer progression and survival. This bioinformatics analysis provides a 
foundation for future more detailed, functional, and molecular analyses aimed at dissecting such 
functional differences.  
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1. Introduction 
Wnt signaling functions in normal development and stem-cell-mediated homeostasis; and also, 
in the etiology of disease, such as cancer [1,2]. The best understood Wnt signaling mechanism is a 
nuclear β-catenin-mediated signal transduction pathway regulating transcriptional gene expression 
[3]. Wnt pathway-promoted nuclear β-catenin proteins regulate transcription indirectly by binding 
to and altering multi-protein complexes associated with sequence-specific DNA binding factors, 
predominantly of the Lymphoid Enhancer Factor/T-Cell Factor (LEF/TCF) protein family [4,5]. 
Humans have four genes encoding LEF/TCF proteins, similar to other mammals and most 
vertebrates [6,7]. With little or without nuclear β-catenin protein, LEF/TCF proteins mostly mediate 
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transcriptional repression of Wnt-target genes. Moreover, with increased nuclear β-catenin levels, 
LEF/TCF proteins generally mediate transcriptional activation [8].  
Different LEF/TCF genes are expressed in different tissues and at different stages, and together 
with alternative splicing and alternative promoter use this results in a rich variety of differentially 
expressed LEF/TCF protein isoforms [7,9,10]. There is considerable functional redundancy between 
different LEF/TCF proteins, yet also emerging evidence for quantitative and even qualitative 
differences. Quantitative difference refers here to different LEF/TCF protein isoforms being more or 
less effective at mediating transcriptional repression with little or without nuclear β-catenin protein; 
versus transcriptional activation with increased nuclear β-catenin levels [4,6,11,12]. Qualitative 
difference refers to the possibility of different LEF/TCF protein isoforms binding to different 
cis-regulatory target DNA sequences and thereby regulating different Wnt target genes [13,14]. 
Wnt signaling is particularly relevant in colorectal cancer, since the vast majority of colorectal 
cancers harbor Wnt/β-catenin pathway-activating mutations [15], which contrasts with a normal 
benevolent role in regulating stem-cell-mediated maintenance of intestinal and colorectal epithelial 
tissue [16,17]. Roles for LEF/TCF proteins has been studied in tissue-culture and animal models of 
intestinal stem cells and colorectal cancer, which suggested roles for TCF7L2 and TCF7 in normal 
colorectal tissue, where LEF1 and TCF7L1 are silent, but strong expression in colorectal tumor of 
LEF1 [9,18–21] and TCF7 [22,23].  
Here, we aimed to assess whether predictions about Wnt signaling in colorectal cancer from 
tissue-culture and animal model systems could be confirmed by a meta-analysis of compatible 
transcriptomics studies of paired normal and tumor biopsy samples from human patient, and 
whether specific LEF/TCF gene-correlated transcriptomes imply LEF/TCF gene-specific function in 
normal or tumor tissue.  
Our meta-analysis of transcriptomics studies provides a clear picture of altered LEF/TCF gene 
expression, confirming TCF7L2 in normal and LEF1 expression in tumor tissue, but also higher than 
expected TCF7L1 in normal and relatively higher TCF7 expression in tumor tissue. Specific LEF/TCF 
gene expression is indeed correlated with differences in the overall transcriptome, with some of 
these differences suggestive of relevance for tumor progression. 
2. Materials and Methods  
Publically available data were searched within the databases Gene Expression Omnibus (GEO) 
and ArrayExpress using ‘colon cancer’ or ‘colorectal cancer’ as search words. From this list only 
studies that satisfied the following conditions were selected: a) samples from human biopsies (i.e. no 
rodent models or cell line data), b) paired samples from tumor with nearby normal tissue, c) a 
sample size of at least four patients in order to conduct meaningful statistical analyses. The selected 
studies with Genomic Spatial Event (GSE) database accession numbers are listed in Table 1. As a first 
exploratory analysis step a principal component analysis (PCA) based on scaled and centered 
variables was conducted using the prcomp function within R. The score plots of the first two 
principal components were studied to check for the separation of tumor and normal samples 
Meta-Analysis of differential expression between tumor and normal for the eight selected genes 
of interest (Figure 1) was conducted using the R-package metafor [24]. The standardised mean 
difference (SMD) was chosen as a measure of differential gene expression here and a ‘random 
effects’ model was used for weighting of the studies. The random effects model is used to address 
the heterogeneity between studies caused by differences in study designs, study population and also 
by the different gene expression platforms used. 
The correlation plots (Figure 2) were produced within the R-package corrplot [25]. For the 
meta-analysis of correlation differences between normal and tumor for each of the eight selected 
genes of interest we first selected 18,150 genes that were included in at least two of the studies. For 
each of the eight genes, we then calculated correlations within tumor and normal samples with each 
of the 18,150 other genes. The differences between tumor and normal correlation for each of the 8 × 
18,150 = 145,200 combinations where averaged across the studies and tested against the null 
hypothesis of no correlation by a one-sample t-test, which corresponds to a random effect 
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meta-analysis, where within study variation is assumed to be negligible compared to between study 
variation.   
The organized expression data (Supplementary Table S1B–I) were filtered for standard 
deviation less than 0.2 where correlation coefficients association with a specific gene were ranked in 
all normal or all tumor samples (e.g., Supplementary Table S2), and where mean difference between 
them was independently calculated for p-value less than 0.05 (e.g., Table 2). The top 10 genes were 
presented in a ranked list (Tables 2–4; Supplementary Tables S2–4), and the top 100 list was used for 
gene ontology analysis, excluding the target gene itself (i.e AXIN2 in the AXIN2 list, the specific 
LEF/TCF gene in the specific LEF/TCF gene list etc.). The individual LEF/TCF correlation values 
were compared with each other (Supplementary Figure S1J), and with AXIN2 (Supplementary 
Figure S1K). Gene ontology analysis was carried out on GOrilla (http://cbl-gorilla.cs.technion.ac.il) 
selecting the ‘Two unranked lists of genes’ setting comparing the first 100 genes of the ranked gene 
lists (see above) with the full 18,150 background list of all genes in the analyzed data. The top 5 gene 
ontology terms were listed together with order of magnitude or their p-value if below 0.001. 
Table 1. Data Sets Mined in this Investigation. 
Name Description Reference 
GSE10950 24 colon normal and tumor pairs (48 arrays) [26] 
GSE20842 
Paired samples of tumor and mucosa from a total of 65 patients (130 
arrays). 30 of the patients carried mutated KRAS1. this data set was 
divided into two different studies: one with mutated KRAS (named 
«mutated») and one without (named «wild type»). 
[27] 
GSE25070 
26 pairs of fresh frozen colorectal tumor and matched adjacent 
non-tumor tissue samples (52 arrays). [28] 
GSE44076 98 colorectal cancer patients and their pairs (196 arrays). [29] 
GSE46622 4 colorectal cancer patients and their pairs (8 arrays). [30] 
GSE50760 18 patients, colon and tumor paired (36 arrays). [31] 
3. Results 
3.1. Selection of Transcriptomics Data Sets and Quality Control 
We carefully reviewed publicly available transcriptomics datasets of human colorectal cancer 
samples. We focused on the traditional and longest existing gene expression databases GEO and 
ArrayExpress. We selected published studies with a) sufficient numbers of samples for the intended 
statistical meta-analysis and b) paired samples from tumor with nearby normal tissue (Table 1). A 
similar review of available human RNA-seq datasets at the time did not identify studies with 
sufficient numbers of samples to justify a meaningful meta-analysis. Our initial selection of studies 
therefore contained mainly microarray studies as these form the majority of entries in those 
databases and also because the few RNAseq studies we obtained had either too small a sample size 
or other quality issues. We also note that a joint meta-analysis combining microarray and RNAseq 
data would be quite challenging as the nature of the data (continuous measurements versus 
normalized counts) and the corresponding analysis techniques (linear models versus generalized 
linear models) are fundamentally different. 
Our hypothesis predicts that the transcriptome in tumor tissue would be sufficiently distinct 
from the one in control normal tissue as a prerequisite for our intended meta-analysis. A principal 
component analysis of the selected datasets (Supplementary Figure S1) therefore served as an 
additional quality control confirming separation of the transcriptome between tumor sample and 
normal control in all selected individual studies. The data from Kim et al. [31] showed a somewhat 
less distinct separation of tumor versus normal transcriptome, but a clear enough difference to retain 
this study in our meta-analysis. Another study, GSE46905 [32], which we had originally considered, 
was not taken forward because we could not find sufficiently clear separation between tumor and 
normal transcriptome (Supplementary Figure S2).  
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3.2. Transcriptomics Expression of Eight Selected Genes 
We first tested our hypothesis about differential expression of LEF/TCF genes between tumor 
and normal tissue with forest plots (Figure 1) of all four LEF/TCF genes (TCF7, LEF1, TCF7L1, 
TCF7L2). We chose to monitor additionally the expression of AXIN2, DKK1, FZD7, and LGR5. 
AXIN2 is a direct Wnt target gene [33,34] used here as a reliable indicator of intracellular 
Wnt/β-catenin pathway activity, and because increased expression has been reported in colorectal 
tumor tissue [35]. DKK1 is a direct Wnt target gene [36] with increased expression in many cancers 
[37], however, here DKK1 was chosen particularly because its expression had previously been 
reported to be reduced in colorectal tumor [38]. FZD7 is also a Wnt target gene [39], relevant in 
colorectal cancer [40] and normal intestinal epithelium [41]. LGR5 is a Wnt target gene, which is the 
marker gene for normal adult intestinal stem cells [17], and for particularly aggressive colorectal 
cancer stem cells [16,22,23,42].  
Our meta-analysis reveals that AXIN2 (Figure 1E) is consistently expressed at a higher level in 
tumor relative to normal tissue, and so is LGR5 (Figure 1H), indicating as expected increased 
Wnt/β-catenin signaling activity [35] and increased stem cell identity of tumor tissue [42]. 
Importantly, among the LEF/TCF genes, our meta-analysis also corroborates a switch from relatively 
higher TCF7L2 (Figure 1D) and TCF7L1 (Figure 1C) expression in normal control to relatively higher 
TCF7 (Figure 1A) and LEF1 (Figure 1B) expression in tumor tissue. Our meta-analysis did not 
highlight any dramatic changes in gene expression for the FZD7 and DKK1 genes between normal 
and tumor tissue. 
3.3. Correlation of Expression between Eight Selected Genes 
We next analyzed correlations in gene expression between those eight genes, positive or 
negative, initially in individual matrix plots (Figure 2). As expected, there is in general a positive 
correlation between AXIN2 expression and LGR5 expression (stem cell identity marker). There 
appears also generally a positive correlation between TCF7 and LEF1 expression and between those 
and LGR5 expression, consistent with previous findings in mouse models [22,23]. If these 
correlations were linked to increased Wnt/β-catenin signaling activity, then we would also expect a 
positive correlation between TCF7 and LEF1 expression and AXIN2 expression, which indeed is 
consistent with the data. Interestingly, AXIN2 expression, which indicates Wnt/β-catenin pathway 
activity, is negatively correlated with TCF7L1 expression. Comparing individual blots also suggests 
generally less strong correlation in tumor tissue.  
We combined the transcriptomics data from these different studies in a meta-analysis, which 
provided an even clearer picture (Figure 3). However, we only carried out this meta-analysis with 
data sets from five of the six selected studies (having removed the data set with only a few patients 
and missing LEF1 values, GSE46622 [30]). This meta-analysis allowed us to tease out more clearly 
differences between tumor and normal tissue; with correlations between transcripts among these 
eight genes being mostly much stronger and clearer in normal control tissue (Figure 3A) and 
generally much weaker in tumor samples (Figure 3B,D). Positive correlations linking TCF7 with 
LEF1 and with LGR5 in normal tissue are reduced in tumor tissue, and the negative correlation 
between AXIN2 and TCF7L1 in normal tissue is also reduced in tumor tissue. The exception to this 
rule is a strengthened correlation between AXIN2 and TCF7 expression in tumor tissue. Remarkably, 
our analysis also reveals that FZD7 expression is strongly positively correlated with TCF7L1 
expression. Even more remarkably, this correlation is absent or much reduced in tumor tissue, and 
in the one study that has relevant information on kRAS mutant status in samples [27], it suggests 
that this correlation between TCF7L1 and FZD7 is particularly strong in KRAS-mutant normal tissue 
(Figure 2C), and is strongly reduced in KRAS mutant tumor (Figure 2D). 
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Figure 1. Forest plots of gene expression of all four LEF/TCF genes (A): TCF7, (B): LEF1, (C): TCF7L1, 
(D): TCF7L2, and (E): AXIN2, (F): DICKKOPF-1 (DKK1), (G): FZD7, and (H): LGR5, from six selected 
studies. Columns from left to right indicate: accession no. of study (with GSE20842 [27] separated 
between kras-positive and kras-mutant samples); number of patients in individual studies; 
horizontal segments indicate the standardized mean difference between tumor and normal, and their 
confidence interval, with the size of the square dot being proportional with the weight of the study in 
the meta-analysis using a ‘random effects’ model. The corresponding values are written in the 
column on the right: weight of the individual study in percent as part of the meta-analysis; 
standardized mean difference; and in square brackets confidence interval. The red polygon in the 
bottom of each plot shows the summary estimate based on the random-effect model. Values to the 
left of the midline indicated higher expression in the control relative to the tumor sample, e.g., see 
AXIN2 and LGR5. Individual studies with small sample size (i.e., few patients) as expected often 
have larger confidence intervals (therefore less reliability, e.g., see TCF7 and LEF1 data for GSE46622 
study), but in the meta-analysis (in red) much tighter confidence intervals (therefore higher 
reliability). Note that, among the four LEF/TCF genes, TCF7, LEF1, are expressed higher, while 
TCF7L1, TCF7L2 lower in tumor tissue. 
A B 
C D 
E F 
G H 
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Figure 2. Correlation plot matrix of relative gene expression between eight selected genes in six 
selected studies (A–N), with normal control (A, C, E, G, I, K, M) separated from tumor sample (B, D, 
F, H, J, L, N), and additionally for the GSE20842 [27] between kras-mutant (“mut”) samples (C, D) 
and kras-positive (“wild” as in wildtype) samples (E, F). Blue dots indicate positive and red dots 
negative correlation. The size of the circle and the intensity of the color is proportional to the 
correlation coefficient; therefore, as an internal control, expected diagonal series of large blue dots 
where expression of genes is compared to the expression of the same gene). Missing values in 
GSE46622 [30] is due to low value data for LEF1 in this study. Note positive correlation between 
AXIN2 expression and LGR5, TCF7 and LEF1 expression, yet negative correlation with TCF7L1 
expression, while TCF7L1 and FZD7 expression are positively correlated, though clearly much more 
so in normal control tissue than in tumor. In contrast, the correlation between AXIN2 and TCF7 
expression is clearly more robust in tumor compared to normal tissue. Interestingly, the unearthed 
correlation between TCF7L1 and FZD7 expression appears to be dependent on wild-type kRAS in the 
tumor (compare D with F, yet not in normal control C). 
A B 
C E D F 
G I H J 
K M L N 
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Figure 3. Correlation of transcript expression between eight selected genes (TCF7, LEF1, TCF7L1, 
TCF7L2, AXIN2, DKK1, FZD7 and LGR5) in normal control tissue (A), in tumor tissue (B), and when 
analyzed combined in normal and tumor tissue (C) (negative numbers and graded red highlighting 
indicates negative correlation; positive numbers and graded green highlighting positive correlation). 
(D) Mean difference between normal and tumor tissue of correlation of transcript expression 
between eight selected genes (red highlighting with positive numbers indicates reduced negative 
correlation in tumor tissue; green highlighting with negative numbers indicates reduced, with 
positive numbers increased, positive correlation in tumor tissue; yellow highlighting with positive 
numbers indicates a switch from negative to positive, and with negative numbers to negative, 
correlation in tumor tissue. Note generally reduced correlations in tumor tissue; particularly note, 
reduced positive correlation between TCF7 and LEF1, between TCF7 and LGR5, and between TCF7L1 
and FZD7 expression; and reduced negative correlation between AXIN2 and TCF7L1 expression. 
However, also note exceptional increased positive correlation between AXIN2 and TCF7 in tumor 
tissue. 
3.4. Correlation between Eight Selected Genes and the Rest of the Transcriptome 
We extended the analysis for correlations in gene expression between each of those eight genes 
with the whole rest of the transcriptome. We ranked the TCF7 gene expression-correlated whole 
transcriptome expression (positively and negatively correlated) separately in normal tissue and in 
tumor tissue (Supplementary Table S2A), and then also independently ranked and analyzed the 
greatest transcript correlation differences between tumor and normal tissue (Table 2). In a gene 
ontology analysis, we searched for the suggested association of correlated gene expression with 
biomedical processes. We then repeated this independently for the other LEF/TCF gene 
expression-correlated transcriptomes, and the AXIN2-, DKK1-, FZD7-, LGR5-correlated 
transcriptomes (Table 2, Supplementary Table S1B-I, Supplementary Table S2). 
In normal tissue, both TCF7 and LEF1 expression is positively correlated with gene expression 
associated with the immune system. This correlation with immune system-associated transcripts is 
more generally lost in tumor tissue. In normal tissue TCF7L1 expression is positively, and AXIN2 
expression negatively correlated with gene expression associated with cell adhesion. While in tumor 
tissue TCF7L1, and even more so LEF1 gene expression is correlated with transcripts associated with 
the extracellular matrix (ECM); and expression of AXIN2 with TCF7 is correlated with regulation of 
Wnt signaling (particularly Wnt receptor catabolic processes), with this correlation being stronger in 
tumor than normal tissue. However, we do not find any specific correlation with cyclin D1 (CCND1) 
gene expression [43,44], and BMP4 expression [45] is only specifically correlated with DKK1. 
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Table 2. Correlated Transcriptome. 
  More in Tumor Less in Tumor 
A: Largest Difference in the TCF7-Correlated 
Transcriptome between Tumor and Normal 
Ranked 
Gene List 
Top 10 
NECAB3, TCFL5, ZNRF3, IFT52, SLC2A12, SKP1, 
DYNLRB1, MBNL2, SSX2IP, CAMLG 
WDFY4, TBC1D10C, TRAF3IP3, IKZF1, RASAL3, SP140, LTB, ARHGAP9, 
CD37, SASH3 
Associated 
Gene 
Ontology 
Top 5: 
1. intraciliary transport involved in cilium 
assembly (10−6) 
1. lymphocyte activation (10−27) 
2. intraciliary transport (10−5) 2. immune system process (10−25) 
3. protein-containing complex localization 
(10−4) 
3. regulation of immune system process (10−20) 
4. Wnt signaling pathway (10−4) 4. leukocyte activation (10−20) 
cell surface receptor signaling pathway involved 
in cell-cell signaling (10−4) 
positive regulation of immune system process (10−19)  
B: Largest Difference in the LEF1-correlated 
transcriptome between Tumor and Normal 
Ranked 
Gene List 
Top 10 
SPRR2F, PDGFC, CAB39L, GRP, SOX11, 
COL12A1, ISM1, GLRB, DKK3, OLFML3 
FAIM3, PVRIG, UGT1A10, CD79B, BANK1, PTPRCAP, BLK, NAPSB, 
FCRLA, CD19 
Associated 
Gene 
Ontology 
Top 5: 
1. extracellular matrix organization (10−13)  1. immune system process (10−21) 
2. cell adhesion (10−12)  2. immune response (10−18) 
3. biological adhesion (10−12)  3. regulation of immune system process (10−18)  
4. extracellular structure organization (10−12)  4. regulation of lymphocyte activation (10−15) 
anatomical structure development (10−8) regulation of leukocyte activation(10−14) 
C: Largest Difference in the TCF7L1-correlated 
transcriptome between Tumor and Normal 
Ranked 
Gene List 
Top 10 
DCBLD1, HMHA1, ARHGAP17, SH3KBP1, LXN, 
TMIGD1, SLC24A6, JAG1, LRCH4, VAMP8 
SSX2IP, SAE1, RHEB, CKMT2, CCNI, NAP1L1, BAG2, ZFAND1, PHGDH, 
RPS5 
Associated 
Gene 
Ontology 
Top 5: 
1. angiogenesis (10−4) 1. organic substance metabolic process (10−5) 
2. anatomical structure formation involved in 
morphogenesis (10−4)  
2. cellular metabolic process (10−5)  
3. positive regulation of neuron death (10−4)  3. metabolic process (10−5)  
4. blood vessel endothelial cell proliferation 
involved in sprouting angiogenesis (10−4)  
4. primary metabolic process (10−4)  
regulation of mast cell activation involved in 
immune response (10−4) 
5. nucleotide-excision repair, DNA damage recognition (10−4) 
D: Largest Difference in the TCF7L2-correlated 
transcriptome between Tumor and Normal 
Ranked 
Gene List 
Top 10 
C3orf70, CDC42EP2, DNAJC24, FLJ25758, 
CDRT15, HIG2, CIT, GNG3, C1orf77, TSPAN5 
ACP5, AOAH, SCAND3, PPP1R14C, KIAA0247, DNAH14, NECAP2, 
CHMP1B, C5orf20, CTSD 
Associated 
Gene 
Ontology 
1. optic nerve development (10−4) 1. immune system process (10−6)  
 2. negative regulation of myeloid leukocyte mediated immunity (10−5)  
 3. negative regulation of mast cell activation (10−5)  
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Top 5:  4. negative regulation of eosinophil activation (10−5)  
 
negative regulation of MyD88-dependent toll-like receptor signaling 
pathway (10−5) 
E: Largest Difference in the AXIN2-correlated 
transcriptome between Tumor and Normal 
Ranked 
Gene List 
Top 10 
NKD1, CAB39L, APCDD1, NRXN3, PRSS23, 
LY6G6D, CCDC46, PPP2R2C, HABP4, CKMT2 
GFI1, ADAM28, MFSD1, TOR1B, CD8A, FAS, SPIB, MBP, SLAMF1, RIOK3 
Associated 
Gene 
Ontology 
Top 5: 
1. regulation of cellular localization (10−4)  1. adaptive immune response based on somatic recombination of 
immune receptors built from immunoglobulin superfamily domains (10−5)  
2. cellular response to gamma radiation (10−4)  2. lymphocyte mediated immunity (10−5)  
3. Wnt signaling pathway (10−4)  3. immune response (10−5)  
4. regulation of cell communication (10−4) 
5. regulation of vascular endothelial growth 
factor receptor signaling pathway (10−4) 
4. immune system process (10−5)  
5. pancreatic A cell differentiation (10−5) 
F: Largest Difference in the DKK1-correlated 
transcriptome between Tumor and Normal 
Ranked 
Gene List 
Top 10 
MIZF, BMP4, SLITRK6, OR7E91P, MGC34774, 
PANK3, PAQR8, ATAD4, GDA, GPR110 
UCHL5IP, DPH1, LOC399744, PDGFA, MEIS3P1, PER2, NDNL2, MAFK, 
CCND2, STARD13 
Associated 
Gene 
Ontology 
Top 5: 
1. lipid catabolic process (10−5)  1. positive regulation of ATPase activity (10−4) 
2. cellular lipid catabolic process (10−4)   
3. molting cycle process (10−4)   
hair cycle process (10−4)  
4. lipid catabolic process (10−5)   
G: Largest Difference in the FZD7-correlated 
transcriptome between Tumor and Normal 
Ranked 
Gene List 
Top 10 
RNFT1, DERL1, FAM49B, FAM91A1, CA13, 
SLC7A8, ARFGEF1, HTATIP2, B3GNT2, 
NUP62CL 
FGFBP2, KANK1, SORBS2, GPR155, TSHZ1, PCSK2, CCDC92, SEMA3A, 
FAM149A, HOXA10 
Associated 
Gene 
Ontology 
Top 5: 
1. Golgi reassembly (10−4) 1. anatomical structure development (10−4)  
 2. developmental process (10−4)  
 3. regulation of heart rate by chemical signal (10−4)  
 4. proximal/distal pattern formation (10−4)  
 negative regulation of protein polymerization (10−4) 
H: Largest Difference in the LGR5-correlated 
transcriptome between Tumor and Normal 
Ranked 
Gene List 
Top 10 
ZAK, ISM2, SRPK3, SATB1, GRP, ACOT9, 
ZCCHC12, KLHL23, HEY2, FAHD2B 
DHDDS, MGC29506, FAIM3, CHP2, FAM46C, SLC46A3, TMBIM6, 
POU2AF1, MEI1, BCL2L15 
Associated 
Gene 
Ontology 
Top 5: 
1. regulation of systemic arterial blood 
pressure by atrial natriuretic peptide (10−5)  
1. B cell receptor signaling pathway (10−10)  
2. regulation of developmental process (10−5)  2. adaptive immune response (10−9)  
3. extracellular matrix organization (10−5)  3. immune system process (10−7)  
4. extracellular structure organization (10−4)  4. antigen receptor-mediated signaling pathway (10−6)  
regulation of systemic arterial blood pressure by 
hormone (10−4) 
immune response (10−6) 
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3.5. Comparison of Lef/Tcf-Correlated Transcriptomes 
Subsequently, we explicitly focused on comparing the different LEF/TCF gene-correlated 
transcriptomes with each other (Table 3, Supplementary Tables S1J and S3). A compound analysis of 
differences between all LEF/TCF gene-correlated transcriptomes (Supplementary Table S3) reveals 
that, overall, differences between TCF7L1- and TCF7L2-correlation dominate in normal tissue, while 
in tumor tissue, though they are still prominent, differences in particular with TCF7-correlation and 
also with LEF1-correlation become more noticeable. These overall differences can be associated with 
extracellular matrix, angiogenesis, and cell adhesion. However, clearly this compound analysis by 
itself does not reflect any meaningful biological or clinical situation and this gene ontology 
association here only serves to guide more specific analyses (Table 3).  
Detailed pairwise analysis of these prominent differences between TCF7L1- and 
TCF7L2-correlation in normal tissue suggests a stronger association of TCF7L1-correlated transcripts 
with the extracellular matrix, and a stronger association of TCF7L2-correlated transcripts with cell 
junctions and cell adhesion; but interestingly, in tumor tissue TCF7L1 expression is more strongly 
correlated with transcripts associated with cell adhesion; and also with angiogenesis. Consistent 
with the single LEF/TCF gene correlation analysis above, any comparison between either TCF7 or 
LEF1, on the one hand and with either TCF7L1 or TCF7L2, on the other, highlights the higher 
correlation of expression of TCF7 and LEF1 with a transcriptome associated with the immune 
system. Remarkably, these pairwise comparisons also reveal that any link to extracellular matrix 
(ECM) generally excludes TCF7 and TCF7L2, but generally includes both TCF7L1 and LEF1; TCF7L1 
more in normal tissue, and LEF1 more in tumor. Comparison between these two, i.e. between 
TCF7L1- and LEF1-correlated transcription, also reveals a potential correlation of LEF1 expression 
with double strand break DNA repair in tumor. Pairwise comparison with TCF7, suggests LEF1 in 
tumor may also be correlated with regulation of cell migration. The same comparison suggests a 
stronger correlation for TCF7 in normal tissue to transcripts associated with sensory perception, 
which seems difficult to explain. 
3.6. Comparison between AXIN2- and LEF/TCF-Correlated Transcriptomes 
Since LEF/TCF proteins are known to function generally as nuclear effectors of WNT/β-catenin 
signal transduction [3,4,6], we compared individual LEF/TCF gene expression-correlated 
transcriptomes with the AXIN2 expression-correlated transcriptome (Table 4; Supplementary Table 
S1K and S4), employing AXIN2 expression again as an indicator of WNT/β-catenin pathway activity. 
A compound analysis of overall differences between the AXIN2- and all LEF/TCF gene 
expression-correlated transcriptomes (Supplementary Table S4) reveals that most differences are 
with the TCFL1-correlated transcriptome, particularly in normal tissue, suggesting a link with cell 
adhesion.  
The direct comparison between the AXIN2- and all TCF7L1 gene expression-correlated 
transcriptomes confirms the higher correlation of TCF7L1 expression with cell adhesion-associated 
transcripts, not just in normal tissue, but also in tumor tissue. Remarkably, LEF1 shares with TCF7L1 
this stronger link to cell adhesion in tumor tissue, and also an association in normal tissue with 
muscle, which seems difficult to explain, but could somehow be linked to shared molecular 
machinery functioning in cell migration. The AXIN2-correlated transcriptome in tumor tissue 
trumps however, in its association with transcripts indicating regulation of Wnt signaling, 
particularly Wnt receptor catabolic processes, and contrasting with all LEF/TCF-correlated 
transcriptomes, apart from, interestingly, that of TCF7. 
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Table 3. Comparison of LEF/TCF-Correlated Transcriptomes. 
   Higher TCF7 Correlation Higher LEF1 Correlation 
A: Differences between TCF7 and LEF1 
Correlated Transcriptomes 
In 
Normal 
Tissue 
Ranked Gene List 
Top 10 
FLJ46257, AADACL4, OR4D9, OR8U9, OR1S1, KRTAP6-1, 
TRIM6-TRIM34, OR5H15, OR4M2, OSTN 
IFNA1, AADACL1, LEF1, SCYL1BP1, 
EIF4EBP3, POLR2J3, FAM18B, WDR40A, 
NME1-NME2, RTCD1, OR51A2 
Associated Gene 
Ontology Top 5 
1. detection of chemical stimulus involved in sensory 
perception of smell (10−30)  
2. detection of chemical stimulus involved in sensory 
perception (10−29) 
3. detection of stimulus involved in sensory 
perception (10−27) 
4. detection of stimulus (10−23) 
5. G protein-coupled receptor signaling pathway 
(10-16) 
1. flavone metabolic process (10−4)  
2. flavonoid glucuronidation (10−4) 
In Tumor 
Tissue 
Ranked Gene List 
Top 10 
GBL, C2orf24, NECAB3, EIF6, MGAT4B, ACOT8, ACSF3, 
TMUB1, SLC35C2, OR2J3 
1. positive regulation of mitochondrial translation 
(10−4) 
2. sulfur compound metabolic process (10−4) 
3. glycerol metabolic process (10−4) 
4. positive regulation of cellular amide metabolic 
process (10−4)  
5. alditol metabolic process (10−4)  
C5orf13, C14orf139, ST3GAL6, ECM2, 
DOCK10, PDGFC, SLFN11, MDFIC, SGIP1, 
RASGRP3 
1. extracellular structure organization 
(10−11)  
2. extracellular matrix organization (10−10)  
3. anatomical structure morphogenesis 
(10−8)  
4. regulation of cell migration (10−8) 
5. regulation of cell motility (10−7)  
B: Differences between TCF7- and 
TCF7L1-correlated transcriptomes 
In 
Normal 
Tissue 
Ranked Gene List 
Top 10 
HMHA1, PTPN7, SP140, PTPRCAP, CD6, FAIM3, 
DENND2D, SYK, LCK, DENND1C 
1. regulation of immune system process (10−15) 
2. regulation of lymphocyte activation (10−15) 
3. regulation of cell activation (10−14) 
4. regulation of leukocyte activation (10−14) 
5. immune system process (10−13)  
FAM127C, JAZF1, TSPAN2, ZEB1, CAP2, 
FBXL2, MEIS1, CYS1, AGTR1, EHBP1 
1. muscle system process (10−10)  
2. muscle contraction (10−9) 
3. actin-mediated cell contraction (10−5) 
4. system process (10−5)  
5. regulation of muscle contraction (10−5)  
In Tumor 
Tissue 
Ranked Gene List 
Top 10 
C20orf118, VDAC1, EIF6, ETV4, MST4, GPR89A, TRAP1, 
UBAC2, EPHA1, ARPC1B 
1. chromosome segregation (10−5) 
2. pteridine-containing compound metabolic process 
(10−5) 
3. pteridine-containing compound biosynthetic process 
(10−5) 
4. viral process (10−5)  
5. symbiont process (10−4)  
TMEM91, PLAC9, FAM127C, SDPR, CAND2, 
TANC2, SYN2, C6orf204, RHOJ, ADH1B 
1. cell adhesion (10−5)  
2. biological adhesion (10−5)  
3. cyclic nucleotide metabolic process (10−5)  
4. cGMP metabolic process (10−4)  
5. melanocyte differentiation (10−4)  
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C: Differences between TCF7- and 
TCF7L2-correlated transcriptomes 
In 
Normal 
Tissue 
Ranked Gene List 
Top 10 
FAM113B, GRAP, LYL1, HVCN1, CXCR5, FAM65B, 
FAM129C, LIMD2, KRI1, CCL21 
1. lymphocyte activation (10−6) 
2. regulation of T cell activation (10−6)  
3. B cell activation (10−5) 
4. leukocyte activation (10−5)  
5. positive regulation of double-strand break repair via 
homologous recombination (10−5)  
CCDC68, ASAP2, B3GNT2, TMEM56, SH3RF1, 
FAM177A1, FAM126B, UGP2, MICALCL, 
MOBKL2B 
1. actin filament-based process (10−5)  
2. actin cytoskeleton organization (10−5)  
3. regulation of cytoskeleton organization 
(10−5)  
4. forebrain astrocyte development (10−5)  
5. midbody abscission (10−4)  
In Tumor 
Tissue 
Ranked Gene List 
Top 10 
TMEM198, PRPF6, GTF3C5, EIF3G, DSN1, SLC35C2, 
NECAB3, EIF6, RELL2, SNHG11 
1. heterocycle metabolic process (10−4) 
2. cellular nitrogen compound metabolic process (10−4)  
3. nucleobase-containing compound metabolic process 
(10−4)  
4. snRNA modification (10−4)  
5. viral translational termination-reinitiation (10−4)  
C18orf32, HEATR5A, ASAP2, SGMS2, 
DDX60L, FGD4, LGR4, SMCHD1, TBC1D12, 
ZG16 
1. regulation of viral-induced cytoplasmic 
pattern recognition receptor signaling pathway 
(10−4)  
2. sphingomyelin biosynthetic process 
(10−4)  
3. regulation of MDA-5 signaling pathway 
(10−4)  
D: Differences between LEF1- and 
TCF7L1-correlated transcriptomes 
In 
Normal 
Tissue 
Ranked Gene List 
Top 10 
HMHA1, DENND2D, UGT1A10, SSH2, BCL11B, SP140, 
CD6, STX19, ZNF101, EZH2 
1. regulation of immune system process (10-11) 
2. immune system process (10-11) 
3. regulation of cell activation (10-10) 
4. regulation of lymphocyte activation (10-10)  
5. regulation of cytokine production (10-9)  
FAM127C, LOC401431, CAP2, WDR86, DDR2, 
MAP6, FILIP1, ILK, GNAO1, ZEB1 
1. muscle contraction (10−7)  
2. muscle system process (10−6) 
3. system process (10−6)  
4. supramolecular fiber organization (10−5)  
5. cytoskeleton organization (10−5)  
In Tumor 
Tissue 
Ranked Gene List 
Top 10 
VDAC1, NCAPG2, NOMO3, EZH2, GPR89A, FAM72A, 
NOP16, DNAJC2, USP6NL, C20orf118 
1. nucleic acid metabolic process (10−9)  
2. DNA metabolic process (10−8) 
3. double-strand break repair via homologous 
recombination (10−8)  
4. nucleobase-containing compound metabolic process 
(10−7)  
5. cell cycle process (10−7)  
TMEM91, SYPL2, PLAC9, DEFB124, ADH1B, 
ZCWPW2, NBPF10, JPH4, RNF165, LOC401431 
1. synaptic signaling (10−5)  
2. trans-synaptic signaling (10−5)  
3. modulation of chemical synaptic 
transmission (10−4)  
4. regulation of trans-synaptic signaling 
(10−4)  
5. cell communication (10−4)  
E: Differences between LEF1- and 
TCF7L2-correlated transcriptomes 
In 
Normal 
Tissue 
Ranked Gene List 
Top 10 
LYL1, GRAP, HHEX, STMN3, FAM113B, MFNG, EIF3G, 
FXYD5, FSCN1, DNMT1 
1. immune system process (10−8) 
2. regulation of dendritic cell dendrite assembly (10−7)  
3. B cell activation (10−6) 
4. dendritic cell chemotaxis (10−6) 
5. positive regulation of biological process (10−6)  
ASAP2, XIAP, MED13, TBC1D12, 
FAM120AOS, ACAP2, BCL2L15, MPZL3, 
FNIP2, SH3RF1 
1. positive regulation of protein localization 
to endosome (10−5)  
2. negative regulation of cytoplasmic 
translational elongation (10−5) 
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3. forebrain astrocyte development (10−5)  
4. regulation of protein localization to 
endosome (10−5)  
5. 5-methylcytosine catabolic process (10−5)  
In Tumor 
Tissue 
Ranked Gene List 
Top 10 
STRA6, CDH11, PDGFC, DIO2, ADAMTSL2, HEYL, 
TMEM204, NUAK1, SGIP1, VCAN 
1. extracellular matrix organization (10−20)  
2. extracellular structure organization (10−19)  
3. animal organ morphogenesis (10−11)  
4. anatomical structure morphogenesis (10−10)  
5. developmental process (10−10)  
UGT1A10, ZNF774, VPS37B, ASAP2, HK2, 
LGR4, ZG16, EZR, FGD4, TSPAN15 
1. flavone metabolic process (10−4)  
2. negative regulation of cytokine secretion 
(10−4)  
3. flavonoid glucuronidation (10−4)  
4. regulation of cellular response to insulin 
stimulus (10−4)  
5. negative regulation of cytokine 
production (10−4) 
F: Differences between TCF7L1- and 
TCF7L2-correlated transcriptomes 
In 
Normal 
Tissue 
Ranked Gene List 
Top 10 
TSPAN18, FAM127A, FAM127C, CLIP3, EFEMP2, 
ZBTB47, DACT3, EHD2, CFL2, DBN1 
1. extracellular matrix organization (10−8)  
2. extracellular structure organization (10−7)  
3. muscle structure development (10−7) 
4. developmental process (10−7) 
5. biological adhesion (10−7)  
TMIGD1, NDFIP2, RAB11FIP1, TMEM45B, 
CDCP1, CLIC5, TMEM87B, BCL10, ABHD3, 
PTPN3 
1. cell-cell junction organization (10−9) 
2. cell junction organization (10−8)  
3. cardiac muscle cell-cardiac muscle cell 
adhesion (10−8)  
4. bundle of His cell-Purkinje myocyte 
adhesion involved in cell communication (10−6) 
5. regulation of action potential (10−6) 
In Tumor 
Tissue 
Ranked Gene List 
Top 10 
FAM127C, TMEM91, WTIP, DEFB124, RASL12, RAMP3, 
NRIP2, PALM, MAP6, TSPAN18 
1. cell adhesion (10−10)  
2. biological adhesion (10−10)  
3. angiogenesis (10−8)  
4. extracellular matrix organization (10−8)  
5. anatomical structure formation involved in 
morphogenesis (10−8)  
C9orf152, PKP2, F2RL1, C11orf53, MRPS35, 
TWF1, GNPNAT1, PLEK2, BCL10, TMPO 
1. nucleobase-containing small molecule 
metabolic process (10−6)  
2. nucleotide-sugar metabolic process (10−5)  
3. carbohydrate derivative metabolic 
process (10−5)  
4. cell-cell junction organization (10−4)  
5. cell junction organization (10−4) 
Comparison of transcriptome differentially correlated with LEF/TCF gene expression. Pairwise differences between two LEF/TCF genes in transcriptome 
correlation, comparing TCF7 with LEF1 (A), TCF7 with TCF7L1 (B), TCF7 with TCF7L2 (C), LEF1 with TCF7L1 (D), LEF1 with TCF7L2 (E) and TCF7L1 with TCF7L2 
(F). (GO terms listed if p-value <10−3, shaded if 10−4 < 10−5, in normal font if 10−6 < 10−9, and in bold if <10−10). Also see Suppl. Table S1J and Suppl. Table S3. 
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Table 4. Comparison between AXIN2- and LEF/TCF-Correlated Transcriptomes. 
   Less TCF7 Correlation Higher TCF7 Correlation 
A: Differences between AXIN2- and 
TCF7  correlated transcriptomes 
In 
Normal 
Tissue 
Ranked Gene List 
Top 10 
AADACL1, FLJ21511, SCYL1BP1, RICS, WDR40A, 
IQCK, MAK10, DKFZP564O0823, SPTLC1, FAM18B 
FAM65B, WDFY4, CXCR5, GAPT, SASH3, HVCN1, 
OR5H15, LIMD2, PRKCB, FAM129C 
Associated Gene 
Ontology Top 5 
1. no GO enrichment found (<10−3) 1. lymphocyte activation (10−21)  
 2. leukocyte activation (10−18)  
 3. immune system process (10−18) 
 4. cell activation (10−16)  
5. regulation of immune system process (10−16) 
In Tumor 
Tissue 
Ranked Gene List 
Top 10 
ZNF776, UGT1A4, OR1L6, C10orf99, SIPA1L2, POLG2, 
CCDC46, EXPH5, ZNF283, PSMAL 
OR4F5, OR4B1, C19orf35, OR5H15, OR2W5, NECAB3, 
OR2G3, ARPC1B, TMEM198, PLOD3 
Associated Gene 
Ontology Top 5 
1. mitochondrion morphogenesis (10−4)  1. detection of chemical stimulus involved in sensory 
perception of smell (10−7)  
2. regulation of inner ear receptor cell 
differentiation (10−4)  
2. detection of chemical stimulus (10−7) 
3. regulation of inner ear auditory receptor cell 
differentiation (10−4)  
3. detection of stimulus involved in sensory perception 
(10−6)  
4. regulation of mechanoreceptor differentiation 
(10−4) 
4. detection of stimulus (10−6)  
5. G protein-coupled receptor signaling pathway (10−4) 
B: Differences between AXIN2- and 
LEF1- correlated transcriptomes 
In 
Normal 
Tissue 
Ranked Gene List 
Top 10 
RNF43, FAM84A, PWP2, AIFM3, ATP7B, HIST2H3C, 
EHF, LPAR2, RICS, ENTPD6 
SPP1, C7, AP1S2, SLC16A4, COPZ2, DFNA5, KCNMB1, 
ITGA1, TRPS1, PDGFRL 
Associated Gene 
Ontology Top 5 
1. epithelial cell differentiation (10−5) 1. muscle system process (10−8)  
2. negative regulation of stem cell proliferation (10−5) 2. muscle contraction (10−6)  
3. epithelial cell morphogenesis involved in placental 
branching (10−5) 
3. relaxation of muscle (10−6)  
4. developmental process involved in reproduction 
(10−4) 
5. negative regulation of epidermis development 
(10−4) 
4. relaxation of vascular smooth muscle 
5. regulation of immune system process (10−16) 
In Tumor 
Tissue 
Ranked Gene List 
Top 10 
LLGL2, C10orf99, SLC25A10, FAM83F, MPST, PARS2, 
EPHB2, RNF43, ZNF576, INPP5J 
RFTN1, VCAN, FAP, ZEB2, TSHZ3, MEIS1, SULF1, 
COL12A1, PDGFC, PDGFRB 
Associated Gene 
Ontology Top 5 
1. Wnt receptor catabolic process (10−5)  1. cell adhesion (10−17)  
2. glucuronate catabolic process (10−4)  2. biological adhesion (10−17)  
3. glucuronate catabolic process to xylulose 
5-phosphate (10−4) 
3. anatomical structure morphogenesis (10−12)  
xylulose 5-phosphate biosynthetic process (10−4) 
4. extracellular matrix organization (10−12)  
5. extracellular structure organization (10−11) 
4. Wnt receptor catabolic process (10−5)   
C: Differences between TCF7- and 
TCF7L2-correlated transcriptomes 
In 
Normal 
Tissue 
Ranked Gene List 
Top 10 
EHF, C9orf152, GRHL2, LOC57228, MYO6, TOX3, 
FAM84A, MAP7, ACSM3, IHH 
FAM127C, PCDH7, ZEB1, GLI3, COPZ2, FAM129A, 
NEXN, RBPMS2, FERMT2, BHMT2 
Associated Gene 1. epithelial cell differentiation (10−8)  1. muscle system process (10−9) 
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Ontology Top 5 2. columnar/cuboidal epithelial cell differentiation 
(10−6)  
2. muscle contraction (10−9)  
3. regulation of microvillus organization (10−5)  3. cell adhesion (10−7) 
4. actin filament bundle organization (10−5)  
5. epidermal cell differentiation (10−5) 
4. biological adhesion (10−7)  
5. anatomical structure morphogenesis (10−6) 
In Tumor 
Tissue 
Ranked Gene List 
Top 10 
C20orf118, C9orf152, GGH, VWA2, VDAC1, C19orf48, 
LLGL2, MCM4, PDCD11, RNF43 
TMEM91, FAM127C, PLAC9, SDPR, RHOJ, LATS2, 
TNFSF12, C16orf45, FERMT2, TENC1 
Associated Gene 
Ontology Top 5 
1. nitrogen compound metabolic process (10−6)  1. cell adhesion (10−11) 
2. organic substance metabolic process (10−5)  2. biological adhesion (10−11)  
3. macromolecule metabolic process (10−5)  3. organ growth (10−5)  
4. cellular metabolic process (10−5)  
5. Wnt receptor catabolic process (10−5) 4. bone growth (10
−5)  
 5. cyclic nucleotide metabolic process (10−5) 
D: Differences between LEF1- and 
TCF7L2-correlated transcriptomes 
In 
Normal 
Tissue 
Ranked Gene List 
Top 10 
MMS19, KRI1, AOF2, MFF, FRAG1, C9orf163, RPL29P2, 
EIF3B, RBM35B, MFRP 
SMCHD1, RNF19A, RGP1, PALM2-AKAP2, CWC22, 
FLJ20184, DENND5B, MPZL3, FAM108B1, C18orf32 
Associated Gene 
Ontology Top 5 
1. translational initiation (10−10)  1. regulation of protein polyubiquitination (10−4)  
2. nucleic acid metabolic process (10−9) 2. negative regulation of cellular protein localization 
(10-4)  
3. RNA metabolic process (10−8)  regulation of cellular protein catabolic process (10−4) 
4. RNA processing (10−7)  
5. viral transcription (10−7) 3. regulation of protein polyubiquitination (10
−4)  
 4. negative regulation of cellular protein localization 
(10−4)  
In Tumor 
Tissue 
Ranked Gene List 
Top 10 
LY6G6D, CAB39L, APCDD1, NKD1, DPEP1, KRT23, 
NOTUM, STRA6, ADAMTSL2, SESN1 
C18orf32, SMCHD1, ASAP2, EIF4E3, SLC45A3, VAPA, 
MIA3, KITLG, DDX60L, LGR4 
Associated Gene 
Ontology Top 5 
1. negative regulation of Wnt signaling pathway 
(10−5)  
1. positive regulation of multicellular organismal 
process (10−5)  
2. Wnt receptor catabolic process (10−5)  2. multivesicular body sorting pathway (10−5)  
3. pulmonary valve morphogenesis (10−5) 3. negative regulation of cell-cell adhesion (10−5)  
4. regulation of Wnt signaling pathway (10−4)  
4. positive regulation of viral release from host cell 
(10−5) 
5. regulation of locomotion (10−5) 
5. receptor catabolic process (10−4)  
Comparison of the AXIN2-correlated transcriptome with the TCF7- (A), LEF1- (B), TCF7L1- (C), TCF7L2- (D) -correlated transcriptomes in normal and tumor tissue. 
(gene list top 10 genes and top 5 GO terms listed if p-value <10−3, shaded if 10−4 < 10−5, in normal font if 10−6 < 10−9, and in bold if <10−10). Also see Suppl. Table S1K. 
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4. Discussion 
4.1. Meta-Analysis of Human Colorectal Cancer Biopsy Transcripome Studies 
After careful selection of individual studies, our meta-analysis reveals a much clearer picture 
than any individual study, thereby strongly validating our approach. Particularly notable is the 
dramatic tightening of the confidence intervals of the gene expression of the four LEF/TCF genes and 
another four selected genes in the meta-analysis compared to those of individual studies (Figure 1). 
The meta-analysis of correlation of gene expression between eight selected genes (Figure 3) is also 
much clearer than just comparing individual studies with each other (Figure 2). Generally, our 
meta-analysis substantiates that correlations are stronger in normal control compared to tumor 
samples, consistent with the idea of a certain breakdown of controlled gene expression in tumor 
tissue. An interesting exception to this rule is the stronger association between TCF7 and AXIN2 
expression in tumor tissue, which could suggest some specificity in TCF7-mediated WNT/β-catenin 
signaling in human tumor tissue, supporting earlier such suggestions in the mouse model [23]. Our 
analysis proved particularly informative when dissecting differences in transcriptome correlation 
between the four LEF/TCF genes (Table 3) and with AXIN2 (Table 4), comparing tumor with normal 
tissue samples.  
4.2. Differences in LEF/TCF Gene Expression Correlate with Transcriptomes Indicative of Tumor Progression 
Our meta-analysis reveals associations that are potentially relevant for tumor progression and 
possibly metastasis. Cell adhesion-associated gene expression is correlated with TCF7L2 expression 
specifically in normal tissue, and with LEF1 and TCF7L1 in tumor tissue. Extracellular 
matrix-associated gene expression is also correlated with TCF7L1 specifically in normal tissue and 
with LEF1 expression exclusively in tumor tissue. Furthermore, transcripts indicative of 
angiogenesis are correlated with TCF7L1 in tumor; and transcripts indicative of DNA double-strand 
break repair and of cell cycle progress with LEF1 in tumor. The expression of NFE2L2, a regulator of 
p53 and indicator of poor prognosis, is directly transcriptionally regulated by 
WNT/β-catenin/TCF7L2 in cell culture models of colorectal cancer [46]. In our meta-analysis, 
NFE2L2 is noticeable for the large discrepancy between positive correlation with LEF1 and negative 
correlation with TCF7L1 (Supplementary Table S1J), which clearly substantiates the importance of 
NFE2L2 as an important WNT/β-catenin target gene in human colorectal cancer. 
4.3. Indicators of Cell Migration Are Correlated with LEF1, and Likely also Other LEF/TCF Genes 
There is clear correlation of transcripts indicative of regulation of cell migration with LEF1 in 
tumor tissue, consistent with the previously suggested prognostic value of increased LEF1 
expression in colorectal cancer for both increased metastasis and for shorter survival prospects of 
patients [19,20]. Increased LEF1 expression is associated with several types of cancer and has been 
associated in many tissues with regulation of epithelial-to-mesenchymal transition (EMT) including 
transcriptional activation of EMT effectors, such as N-Cadherin, Vimentin, and Snail [47].  
However, a more complex additional involvement in cell migration of TCF7, TCF7L1 and 
TCF7L2 remains likely. TCF7L1 expression is correlated, but only in normal tissue, with 
muscle-associated transcripts, and specifically with expression of the key EMT inducer ZEB1 [48] 
(Tables 2 and 3). Interestingly, in the mouse, Zeb1 had been described in a mutual feedback 
regulatory loop with Tcf4/Tcf7l2, rather than Tcf3/Tcf7l1 [49]. The marker for cell migration and 
known Wnt target HEF1/NEDD9 [50] is correlated in our analysis specifically with TCF7L2 
expression (Supplementary Table S1J). EphrinB2 (EPHB2) expression in a mouse model of colorectal 
cancer is subject to competing positive regulation by Tcf7l2 and negative regulation by Lef1 [51]. 
Moreover, the related ephrinB3 (EPHB3), a Paneth cell marker and tumor suppressor, has recently 
been linked in cell line models of human colorectal cancer to transcriptional suppression specifically 
by TCF7L1 [52]. Our analysis shows EPHB2 and EPHB3 expression, while positively correlated with 
AXIN2, both negatively correlated with TCF7L1 expression. Among the ephrins, our analysis 
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highlights the disparity for EPHA1 expression between such negative correlation with TCF7L1 in 
contrast to positive correlation with TCF7. Increased TCF7 expression in colorectal cancer had 
previously been shown [22,53] and was recently correlated with cell migration and in extension 
possibly metastasis [54]. However, the expression of TCF7 in normal and tumor tissue is more 
complicated than off and on (see below).  
4.4. TCF7/LEF1 Gene Expression Correlates with Transcriptome Associated with the Immune System 
There is clear correlation throughout our meta-analysis between TCF7/LEF1 expression in 
normal tissue and transcripts associated with the immune system. However, since TCF7/LEF1 
expression is generally low in the control samples from normal tissue (Figure 1), it is likely that the 
few cells expressing any TCF7 and LEF1 in these isolated normal tissue samples belong to the 
immune system, and any differences in amount of TCF7/LEF1 transcripts in these samples may 
reflect varying amounts of immune tissue included in these samples, which would be correlated to 
immune system-typical transcripts, rather than suggesting a switch in target genes regulated by 
TCF7/LEF1 in normal and tumor tissue.  
4.5. Feedback Regulation of Wnt Signaling Components at the Cell Membrane  
Possibly the most surprising insight from this meta-analysis concerns the suggested feedback 
regulation on Wnt signaling components at the cell membrane. Firstly, there is strong correlation of 
TCF7L1 with FZD7 expression, particularly in normal but also in tumor tissue (Figures 2 and 3). 
FZD7 encodes a cell-surface Wnt receptor in intestinal stem cells [41], which has been linked to 
colorectal cancer [55]. However, there appears to be a pattern; gene expression of FZD8, FZD4, and 
FZD3 has a similar positive and specific correlation with TCF7L1, while FZD5 expression is 
negatively correlated with TCF7L1, yet positively correlated with TCF7L2 expression (e.g., 
Supplementary Table S1J). These correlations are weaker in tumor tissues, particularly with FZD3.  
Secondly, AXIN2 expression specifically in tumor tissue is positively correlated with transcripts 
associated with feedback regulation of the Wnt pathway (Table 2), particularly the Wnt receptor 
catabolic process (Table 4). Furthermore, there is a correlation with the expression of genes such as 
RNF43 and ZNRF3, which function as Membrane E3 ligases to promote ubiquitination and 
degradation of Wnt receptor proteins, including FZD receptor proteins [56], and suggestively, 
RNF43 and ZNRF3 are frequently found mutated in colorectal cancer [57,58]. LGR5 functions with 
R-spondin proteins (RSPO) to counteract RNF43 and ZNRF3 and prolong Wnt receptor function at 
the membrane [56,59]. Our analysis indicates that LGR5 expression is positively correlated with 
AXIN2, and particularly with TCF7 in normal tissue (Figure 3); also, the related LGR4 is even more 
strongly correlated with TCF7L2 expression (Table 3, Supplementary Table S2D). NEDD4 and 
NEDD4L were recently identified as regulators of LGR5 protein degradation [60]. In our analysis, 
NEDD4 expression (but not NEDD4L) is conspicuous, initially for being differentially correlated 
with AXIN2 expression, negatively in normal tissue and positively in cancer tissue; and additionally, 
for being positively correlated with TCF7L1 in normal tissue, which is opposite to AXIN2, but being 
positively correlated with TCF7 expression in tumor tissue, as AXIN2. These findings are consistent 
with the suggested role of NEDD4 as a tumor suppressor in colorectal cancer. Among the R-spondin 
genes, RSPO2 expression is clearly correlated with TCF7L1, but only in normal tissue, while RSPO3 
expression is less strongly correlated with TCF7L1, both in normal and tumor tissue.  
However, generally, any correlation between transcripts associated with this regulation of Wnt 
signaling and particularly Wnt receptor catabolic processes is strongest with AXIN2 and TCF7 
expression, suggesting specifically for WNT/β-catenin/TCF7 signaling to mediate this feedback 
regulatory mechanism in tumor tissue. This may relate to mouse organoid culture growth becoming 
R-spondin-independent with experimental Tcf7 overexpression [23]. 
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4.6. Implications for Molecular Functions of LEF/TCF Proteins and Isoforms 
It is clearly difficult to de-convolute the likely molecular functions of LEF/TCF proteins from 
our transcriptomics meta-analysis; to assess whether there are quantitative differences in the way 
they function as transcriptional repressors or activators; or whether there are qualitative differences 
in the direct target genes they regulate, possibly due to additional or altered DNA-binding ability 
[13,14,61]. However, the strong difference in transcriptome correlation between AXIN2 and TCF7L1 
is striking, while TCF7 generally appeared to show the least differences (Table 4). If we accept 
AXIN2 expression as a proxy for WNT/β-catenin signaling activity, then our analysis is at least 
consistent with TCF7L1 predominantly functioning as a transcriptional repressor and TCF7 
generally predominantly as a transcriptional activator, supporting the concept of a quantitative 
difference between different LEF/TCF factors [6]. It is also striking that LEF1 and TCF7L1 expression 
share a correlation with transcripts associated with cell adhesion and ECM organization. These 
LEF/TCF genes both lack sequences encoding a C-clamp suggesting at least the possibility that the 
C-clamp-missing LEF1 and TCF7L1 proteins are specifically capable of regulating genes involved in 
cell adhesion and ECM organization in a qualitatively different way to C-clamp containing LEF/TCF 
proteins like those encoded by TCF7 and TCF7L2, [14]. 
Our strict selection procedure resulted in six microarray experiments being considered, since 
for any meta-analysis, rigorous quality control is of most importance and we think that our unbiased 
filtering approach provided us with a small but compatible and informative set of studies. We had 
explored whether the available data could be mined for any information indicating expression of 
different LEF/TCF isoforms, but that proved impossible. Our analysis therefore only correlates the 
transcriptome with transcript expression from a LEF/TCF gene, potentially involving several 
potential gene product isoforms. Furthermore, since our analysis focuses on transcriptional 
responses, any post-translational functional modification of LEF/TCF proteins [62,63] remains 
beyond our ability to evaluate. 
However, differences in TCF7 isoform expression between normal and tumor tissue have been 
described [23,63], and our analysis is at least consistent with a different mix of TCF7 isoforms being 
expressed in normal and tumor tissue. More generally, it is well established that alternative isoforms 
are expressed from the same LEF/TCF gene [7,64]. Thus, future RNA-seq studies with deep enough 
sequencing are expected to distinguish different isoforms, as well as reveal regulation by Wnt 
signaling of alternative isoform expression in potential downstream target genes [65]. It would 
therefore be very interesting in a future meta-analysis to include RNAseq experiments from an even 
wider range of databases like cBioPortal [66] to extend the results obtained here. Additionally, future 
detailed functional investigation is needed and promises to be both important and informative.  
5. Conclusions 
Our meta-analysis confirms differences in LEF/TCF gene expression in human colorectal cancer 
tissue and uncovers a correlation of this differential LEF/TCF gene expression with an altered 
transcriptome, which suggests differences in target gene regulation with likely relevance for tumor 
progression and metastasis. The analysis also reveals a likely feedback loop in tumor tissue from 
WNT/β-catenin/TCF7 signaling mediated transcriptional regulation in the nucleus to resulting 
changes in WNT receptor protein abundance at the membrane. Given the importance of 
WNT/β-catenin signaling for colorectal cancer and the diversity of known LEF/TCF expression and 
protein function, our analysis provides an important foundation for future studies to investigate 
LEF/TCF function and differential isoform expression in more detail. 
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